Rani Therapeutics Holdings RANI
Rani Therapeutics Holdings reports $7.73 million net loss
Rani Therapeutics Holdings (RANI) filed a 10-Q with the SEC on Nov 9, 2026, 5:23 pm ET. Source: the filing on SEC EDGAR.
- Form
- 10-Q
- Filed
- Importance
- Notable
- Accession
- 0001193125-26-453872
- Revenue: $1.71 million for Q3 2026
- Net loss: $7.73 million for Q3 2026
- Diluted EPS: -$0.04 for Q3 2026
- Cash and equivalents: $3.62 million as of Sep 30, 2026
Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.
What changed since last quarter
1 new risk factor · 1 removed
Compared with the 10-Q for the period ended Jun 30, 2026.
| This filing | Previous | Change vs prior 10-Q | |
|---|---|---|---|
| Revenue | $1.71M | $1.71M | −0.1% |
| Operating income and margin | −$9.22M · -540.3% | −$8.83M · -516.9% | −4.5%, margin −23.4 pts |
| Net income | −$7.73M | −$7.39M | −4.6% |
| Operating cash flow | −$7.76M | −$9.03M | +14% |
| Cash | $3.62M | $4.87M | −26% |
New risk factors (1)
- There can be no assurance that we will be able to regain compliance with the Bid Price Requirement during this second compliance period. If we do not regain compliance within the second compliance period, our Class A common stock will be subject to delisting from Nasdaq.
Removed risk factors (1)
- Alternatively, we may be eligible for an additional 180-calendar day compliance period if we elect to transfer to the Nasdaq Capital Market to take advantage of the additional compliance period offered on that market. To qualify, we will be required to meet the continued listing requirement for market value of…